1-3 of 3
Bindu Thapa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CAR T Cell Exhaustion but Not Ex Vivo Cytotoxicity Is Predictive of Patient Clinical Response: An Interim Analysis of ACIT001/EXC002, a Phase Ib/II Trial of Decentralized Production of CAR T Cells for Treatment of Relapsed/Refractory Aggressive NHL and ALL

Charles Yin, Bindu Thapa, Carina Debes-Marun, Zack Breckenridge, Irwindeep Sandhu, Faisal Khan, Michael P. Chu
Journal: Blood
Blood (2023) 142 (Supplement 1): 2092.
https://doi.org/10.1182/blood-2023-187663
Published: 2023
Journal Articles

Predicting Response of CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL) in ACIT001/EXC002, a Phase Ib Clinical Trial

Bindu Thapa, Carina Debes-Marun, Zack M. Breckenridge, Irwindeep Sandhu, Andrew Daly, Faisal Khan, Michael P. Chu
Journal: Blood
Blood (2022) 140 (Supplement 1): 12681–12682.
https://doi.org/10.1182/blood-2022-165930
Published: 2022
Journal Articles

Alberta Cellular and Immunotherapy (ACIT) 001, Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Michael P. Chu, Zack M. Breckenridge, Andrew Daly, Mona Shafey, Victor A. Lewis, Sunil J. Desai, Peng Wang, Joseph Brandwein, Peter Duggan, Beverly Wilson, Bindu Thapa, Carina Debes-Marun, Irwindeep Sandhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 7466–7467.
https://doi.org/10.1182/blood-2022-165887
Published: 2022